Precision Assignment of Intervention Messages to Promote Physical Activity - Precision AIM
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04972279 |
Recruitment Status :
Active, not recruiting
First Posted : July 22, 2021
Last Update Posted : August 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Risk Factor | Behavioral: Digital message (text + image) | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Official Title: | Phase 1 Clinical Trial to Develop a Personalized Adaptive Text Message Intervention Using Control Systems Engineering Tools to Increase Physical Activity in Early Adulthood |
Actual Study Start Date : | January 2, 2022 |
Estimated Primary Completion Date : | December 15, 2022 |
Estimated Study Completion Date : | December 15, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Aggressive adaptation strategy
Participants receive up to 6 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
|
Behavioral: Digital message (text + image)
Messages can be up to 256 characters of text with an image. "Move more" and "sit less" messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity). |
Experimental: Moderate adaptation strategy
Participants receive up to 3 messages/day to support achievement of their behavior change goal. Messages are only delivered outside of a participant-specific Do Not Disturb window (e.g., 11pm-8am). Messages with coordinating images are selected randomly from three content domains: Move More, Sit Less, and Inspirational Quotes Unrelated to Movement within the first month. The decision rule for each participant will be refined on a monthly basis throughout the 6-month study based upon the accumulating data on how each participant is responding to different messages under different conditions.
|
Behavioral: Digital message (text + image)
Messages can be up to 256 characters of text with an image. "Move more" and "sit less" messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity). |
- Acceptability of messaging at 6 months [ Time Frame: 6 months ]Self-reported preference for more, no change or fewer messages/day based on participant exit interviews coded by two blinded research assistants
- Change in total physical activity volume from run-in period [ Time Frame: Baseline and 6 months ]Actigraph-assessed total activity counts during a 1-week monitoring period at baseline versus end of study
- Change in moderate-to-vigorous physical activity duration from run-in period (baseline) to 6 months(baseline) to 6 months [ Time Frame: Baseline and 6 months ]Actigraph-assessed min/week of moderate (or higher) physical activity duration during a 1 week monitoring period at baseline versus end of study

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 29 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Participants capable of reading, speaking and understanding English and of giving informed consent.
- Participants between the ages of 18-29 years.
- Participants must be free of visual impairment that would interfere with the receipt of text messages on their phone.
- Participants must be willing to wear a Fitbit Versa 3 almost continually (23.5 hours/day) for a 6- month period of time.
- Participants must own an iPhone or Android smartphone that they would be willing to download the custom Precision AIM and Fitbit app onto and sync with a Fitbit Versa 3.
- Participants interested in setting goals to increase their physical activity levels over the 6-month study.
Exclusion Criteria:
- Participants engaging in 150 or more minutes of moderate- or greater intensity PA /week as assessed by a research grade accelerometer.
- Participants engaged in organized programs with mandated physical activity (e.g., varsity sports, ROTC).
- Participants with contraindications to normal physical activity on the Physical Activity Readiness Questionnaire.
- Participants who require an assistive device for mobility or have any other condition that may limit or prevent participation in moderate-intensity physical activity.
- Participants who are pregnant or planning to become pregnant within the next 6 months.
- Participants with a prior diagnosis of cancer, cardiovascular disease, diabetes or metabolic syndrome.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04972279
United States, Pennsylvania | |
The Pennsylvania State University | |
University Park, Pennsylvania, United States, 16802 |
Principal Investigator: | David E Conroy, PhD | The Pennsylvania State University |
Responsible Party: | David E Conroy, Professor, Penn State University |
ClinicalTrials.gov Identifier: | NCT04972279 |
Other Study ID Numbers: |
STUDY00016346 |
First Posted: | July 22, 2021 Key Record Dates |
Last Update Posted: | August 10, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |